What is BTi?
Birth Tissue International, operating within the biotechnology and healthcare sectors, specializes in the donation and utilization of amnion and birth tissue. These vital biological resources are instrumental in facilitating healing and advancing medical treatments. The company's core mission involves educating expectant mothers on the profound benefits of donating afterbirth materials, which can substantially enhance the quality of life for individuals managing a spectrum of medical conditions. BTi actively fosters collaborations with hospitals and healthcare providers to streamline the application of donated tissue in critical medical procedures, including surgeries, advanced wound care, and dental applications. Their target audience encompasses expectant mothers, medical professionals, and patients requiring cutting-edge medical interventions.
How much funding has BTi raised?
BTi has raised a total of $131K across 1 funding round:
Debt
$131K
Debt (2021): $131K with participation from PPP
Key Investors in BTi
PPP
Public-Private Partnership
What's next for BTi?
The substantial late-stage funding BTi has attracted signals a period of accelerated growth and market expansion. This capital injection is likely to be strategically deployed towards scaling operations, enhancing research and development initiatives, and potentially broadening its network of healthcare partnerships. The company's focus on the donation and application of birth tissue positions it to capitalize on the growing demand for regenerative medicine and advanced therapeutic solutions. Future developments may include further clinical validation, expanded service offerings, and increased market penetration within the healthcare industry.
See full BTi company page
